- Home
- MIRM vs NZF Comparison
MIRM vs NZF Comparison
Compare MIRM & NZF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- NZF
- Stock Information
- Founded
- MIRM 2018
- NZF 2001
- Country
- MIRM United States
- NZF United States
- Employees
- MIRM N/A
- NZF N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- NZF Finance Companies
- Sector
- MIRM Health Care
- NZF Finance
- Exchange
- MIRM Nasdaq
- NZF Nasdaq
- Market Cap
- MIRM 2.5B
- NZF 2.3B
- IPO Year
- MIRM 2019
- NZF N/A
- Fundamental
- Price
- MIRM $52.17
- NZF $11.58
- Analyst Decision
- MIRM Strong Buy
- NZF
- Analyst Count
- MIRM 9
- NZF 0
- Target Price
- MIRM $66.22
- NZF N/A
- AVG Volume (30 Days)
- MIRM 413.0K
- NZF 496.8K
- Earning Date
- MIRM 08-06-2025
- NZF 01-01-0001
- Dividend Yield
- MIRM N/A
- NZF 4.67%
- EPS Growth
- MIRM N/A
- NZF N/A
- EPS
- MIRM N/A
- NZF N/A
- Revenue
- MIRM $379,251,000.00
- NZF N/A
- Revenue This Year
- MIRM $35.83
- NZF N/A
- Revenue Next Year
- MIRM $16.83
- NZF N/A
- P/E Ratio
- MIRM N/A
- NZF N/A
- Revenue Growth
- MIRM 69.31
- NZF N/A
- 52 Week Low
- MIRM $36.20
- NZF $9.82
- 52 Week High
- MIRM $54.78
- NZF $12.29
- Technical
- Relative Strength Index (RSI)
- MIRM 56.47
- NZF 33.43
- Support Level
- MIRM $50.96
- NZF $11.53
- Resistance Level
- MIRM $53.59
- NZF $11.68
- Average True Range (ATR)
- MIRM 1.63
- NZF 0.08
- MACD
- MIRM -0.17
- NZF -0.04
- Stochastic Oscillator
- MIRM 53.06
- NZF 10.20
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.